About Shire UK

Shire HQShire UK is an indirect wholly owned subsidiary of Shire plc, a global specialty biopharmaceutical company that works closely with specialist physicians, nurses, pharmacists and other healthcare professionals to develop and market medicines that improve quality of life for patients, their families and carers.

Shire traces its history back to 1986, when a team of entrepreneurs began to capitalize on a number of unmet medical needs. Within its first two years of operation the UK-based specialty pharmaceutical company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer’s and end-stage renal failure.

The UK operation now comprises this original product range, additional speciality pharmaceuticals as well as therapies for genetic disorders.

Through the commitment of our employees, we are aiming to make a difference to patients, their families and carers, as well as to the medical community.

For information about Shire’s commitment to Transparency and adherence to the Association of British Pharmaceutical Industry (ABPI) Code of Practice, please visit Shire’s global corporate website shire.com.

Joint Working Projects

West Lancashire CCG and Shire Pharmaceuticals Limited

West Lancashire CCG and Shire Pharmaceuticals Limited are engaged in Joint Working to help to develop a new multi discipline approach to West Lancashire CCG’s commissioning of ADHD services.

Both parties have committed resources to support this project, which will run from June 2017 – November 2017.

The objective of this Joint Working project is to work towards the delivery of an all age mental health service for the people of West Lancashire. In particular the CCG is reviewing the specification and commissioning of services related to Attention Deficit Hyper Activity Disorder (ADHD).

Designed to support:

  • Patient choice (setting, information, type of care, resources)
  • Reduced waiting times
  • Ensuring patients have an opportunity to set their own goals and that their views are respected
  • Self-care and self-management
  • More effective shared care
  • More effective cross functional working both within the NHS and with other agency partners
  • Training for relevant medical and none medical practitioners, especially on the use of appropriate, effective, and well tolerated medicines.

For further information please contact:

Shire UK - Phil Anderton 07710 919868, phil.anderton@shire.com

Item code: C-ANPROM/UK//0143
Date of preparation: June 2017

 

Improving Paediatric ADHD Services, Heart of England NHS Foundation Trust and Shire Pharmaceuticals Limited

Heart of England NHS Foundation Trust and Shire Pharmaceuticals Limited are engaged in joint working to help develop the Trusts paediatric ADHD service. This project will undertake a pharmacotherapy audit of treatments patients receive to manage their ADHD and develop a new community based ADHD nurse service to run over a period of 18-24 months to provide nurse support for young people with ADHD in their local community setting. The parties have agreed that the Project should be undertaken in accordance with the principles and guidance relating to joint working between the NHS and the pharmaceutical industry. The primary objective of the Project is to bring benefits to patients and improve patient outcomes through high quality and cost effective treatment and management. The financial commitments of both parties are similar and significant and, in total, will fall in the range of £200,000 – £220,000. It is anticipated that the Project will commence in September 2017 and continue for a period of 24 months and will bring benefits to patients, the TRUST and Shire.

It is designed to support:

  • Patient outcomes
  • Reduced waiting times
  • More effective assessment and treatment
  • Training for relevant medical and none medical practitioners.

It is anticipated that a full report on the outcomes from this joint working will be published on completion of the Project in 2019.

For further information please contact:

Dr Renu Jainer, Consultant Community Paediatrician.

Heart of England NHS Foundation Trust. Tel: 01217464474.

Email: renu.jainer@heartofengland.nhs.uk

Hanah Sfar-Gandoura. Senior Service Development Manager. Shire Tel: 07747 747076

Email: hanah.sfargandoura@shire.com

Job no: C-ANPROM/UK//0232
Date of preparation: September 2017